Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Monday announced the the re availability of Zenatane (Isotretinoin Capsules, USP) in 10 mg, 20 mg, 30 mg and 40 mg following approval by the US Food and Drug Administration (USFDA) to treat severe acne as well as prevent certain skin cancers.
The Zenatane (Isotretinoin Capsules, USP) in 10 mg, 20 mg, 30 mg and 40 mg is reportedly the therapeutic equivalent generic version of Accutane and is being launched under an approved Risk Evaluation and Mitigation Strategy (REMS) Programme as well as the US FDA's special restricted iPLEDGE distribution programme.
For the most recent 12 months ending in March 2019, the company's Zenatane (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg brand and generic had US sales of approximately USD525m MAT, according to IQVIA Health.
In addition, the company's Zenatane (Isotretinoin Capsules, USP) are available in 3x10 (30-count) blister packages of 10 mg, 20 mg 30 mg, and 40 mg Capsules, USP.
US FDA approves two applications for first Eliquis (apixaban) generics
Amneal Names George, Kiely and Yanai to Board of Directors
Civica Rx, Hikma to Ship Heparin and Seven Other Essential Injectable Medicines
US FDA grants approval to Meitheal Pharmaceuticals' Enoxaparin Sodium Injection
BioDuro names Dr Kent Payne as president of Global CMC Solutions
US FDA Approves Amneal ANDA for Generic Carafate
Dr Reddy's Laboratories reports availability of Deferasirox Tablets for oral suspension in US market
Amneal Launches Generic Revatio for Oral Suspension and Generic Amicar Tablets
Dr Reddy's Laboratories unveils Bortezomib for Injection 3.5 mg/vial in the US